

# Competitor Analysis: PRAME-Targeted Immunotherapy

<https://marketpublishers.com/r/C537EB6F57EEN.html>

Date: June 2018

Pages: 23

Price: US\$ 177.00 (Single User License)

ID: C537EB6F57EEN

## Abstracts

### Competitor Analysis: PRAME-Targeted Immunotherapy

This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non-small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium. It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.

The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

#### About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

### **1) PRAME-TARGETED IMMUNOTHERAPY**

PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines

PRAME-Selective Cellular & Recombinant Immunotherapies

PRAME-Specific, Multi-Target Adoptive Cell Therapy

### **2) CORPORATE & INSITUTIONAL PRAME IMMUNOTHERAPY R&D PIPELINES**

## I would like to order

Product name: Competitor Analysis: PRAME-Targeted Immunotherapy

Product link: <https://marketpublishers.com/r/C537EB6F57EEN.html>

Price: US\$ 177.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C537EB6F57EEN.html>